LungLife AI, Inc.
(the "Company" or "LungLife")
Appointment of Joint Broker
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect.
Investec Bank plc remains Nominated Adviser and Joint Broker to the Company.
For further information please contact:
| LungLife AI, Inc. | |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO |
|
|
|
|
| Investec Bank plc (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
|
Goodbody (Joint Broker) Tom Nicholson / Stephen Kane |
Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420 |
| | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
| Stephanie Cuthbert / Alice Woodings / Phillip Marriage | Mob: 07980 541 893 / 07407 804 654 / 07867 984 082 |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.